Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $69 from $67 and keeps an Outperform rating on the shares following the Q2 report. The company remains on track to submit its application for rusfertide in polycythemia vera next quarter, with two new candidates nearing clinical testing, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability
- Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress
- Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating
- Protagonist Therapeutics files automatic mixed securities shelf
- Protagonist Therapeutics reports Q2 EPS (55c), consensus (52c)